PEER: Partnering to Enhance Emerging Adults' Response to Programs

Sponsor
University of Rhode Island (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT06115252
Collaborator
University of Texas (Other)
248
1
47.9

Study Details

Study Description

Brief Summary

The goal of this clinical trial (CT) is to learn more about emerging adults' and their peers. Here, we will see how co-participating with a peer in health program might impact brain and behavior change over time.

Eligible youth will be invited to come in for a "Participation Day," during which they and a peer will independently complete questionnaires. With a peer, they will then complete a short health program, and undergo a brain scan (fMRI) while completing activities. Our study team will reach out to each participant individually again 3, 6, and 12 months later to learn about health behaviors over time.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Motivational Interviewing (MI)
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
248 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Partnering to Enhance Emerging Adults' Response to Programs (PEER)
Anticipated Study Start Date :
Mar 1, 2024
Anticipated Primary Completion Date :
Feb 28, 2028
Anticipated Study Completion Date :
Feb 28, 2028

Arms and Interventions

Arm Intervention/Treatment
Experimental: Motivational Interviewing (MI)

Behavioral: Motivational Interviewing (MI)
Motivational interviewing with peer dyads starts with an open-ended exploration of the dyad's hazardous drinking behavior via personal stories about alcohol use. It includes a values clarification task and age-matched norms along with personalized feedback regarding the dyad's alcohol use. The goal of the session is to engage the dyad in a thoughtful conversation about drinking and the implications it may have on their lives, with an eye to bolstering and supporting inherent drive for behavior change.

Outcome Measures

Primary Outcome Measures

  1. Blood oxygen level dependent (BOLD) response to self-talk [Baseline]

    Examine changes in brain activation (BOLD response) as a result of participant's own in-session language

  2. Blood oxygen level dependent (BOLD) response to dyadic exchange [Baseline]

    Examine changes in brain activation (BOLD response) as a result of participants' dyadic in-session language

  3. Pearson correlation of self-talk BOLD response percent signal change with youth health behavior assessed with the Timeline Followback [3-, 6-, and 12-months]

    Association of brain response from Outcome 1 with Timeline Followback change over time

  4. Pearson correlation of dyadic exchange BOLD response percent signal change with youth health behavior assessed with the Timeline Followback [3-, 6-, and 12-months]

    Association of brain response from Outcome 2 with Timeline Followback change over time

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 19 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • within the specified age range

  • agree to be contacted for the 3, 6, and 12 month follow ups

  • provide fully informed consent

Exclusion Criteria:
  • left-handed

  • evidence of brain injury/illness and/or neurological, neurodevelopmental disorder including psychosis and related medications (e.g., antipsychotics; neuroleptics)

  • loss of consciousness ≥ 2 minutes

  • other fMRI contraindications (e.g., unremovable metal on/in body, pregnant)

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University of Rhode Island
  • University of Texas

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sarah Feldstein Ewing, Prochaska Endowed Professor of Psychology, University of Rhode Island
ClinicalTrials.gov Identifier:
NCT06115252
Other Study ID Numbers:
  • R01AA030678
First Posted:
Nov 2, 2023
Last Update Posted:
Nov 2, 2023
Last Verified:
Oct 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 2, 2023